In patients with type 2 diabetes and hypercholesterolemia or mixed dyslipidemia treated with statins, PCSK9 inhibitors significantly reduced LDL-C, non-HDL-C and apoB levels. This evidence concerns the gene PCSK9 and metabolic syndrome.